Protalix BioTherapeutics (PLX) Finished Goods (2012 - 2026)

Protalix BioTherapeutics has reported Finished Goods for 10 years, with the latest figure at $18.0 million in Q2 2026.

• On a quarterly basis, Finished Goods rose 108.05% year-over-year to $18.0 million in Q2 2026; TTM through Jun 2026 was $18.0 million, a 108.05% increase from a year earlier, with the FY2025 full-year figure at $10.4 million, up 90.38% from the prior year.
• Finished Goods was $18.0 million for Q2 2026 at Protalix BioTherapeutics, up from $15.4 million in the prior quarter.
• The five-year high for Finished Goods was $18.0 million in Q2 2026, with the low at $706000.0 in Q3 2024.
• Average Finished Goods over 5 years is $9.5 million, with a median of $9.5 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Finished Goods tumbled 91.46% in 2024, then jumped 1446.32% in 2025.
• Over 5 years, Finished Goods stood at $10.6 million in 2022, then slumped by 45.24% to $5.8 million in 2023, then dropped by 6.28% to $5.4 million in 2024, then jumped by 90.38% to $10.4 million in 2025, then surged by 73.08% to $18.0 million in 2026.
• The last three Finished Goods figures came in at $18.0 million (Q2 2026), $15.4 million (Q1 2026), and $10.4 million (Q4 2025), per Business Quant data.